openPR Logo
Press release

US Antidiabetics Drug Market Outlook 2022 Report

05-07-2018 05:55 AM CET | Health & Medicine

Press release from: Kuick Resarch

“US Antidiabetics Drug Market Outlook 2022” report highlights:

* US Diabetes Epidemiology
* US Antidiabetics Market Overview
* Key Marketed Antidiabetic Drugs in US
* US Biosimilar Insulin Market
* US Antidiabetics Drug Market Future Prospects

Download Report Sample Weblink:

https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics

Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication

Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus

Cataloguing of Antidiabetic Agents
4.1 Antidiabetic: Oral Agents
4.1.1 Biguanides
4.1.2 Thiazolidinediones (TZDs)
4.1.3 Sulfonylureas
4.1.4 Meglitinides
4.1.5 andalpha;- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2

Antidiabetic: Injectable Drugs
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus

US Diabetes Epidemiology
6.1 Prevalence of Type 1 and 2 Diabetes
6.2 Economic Burden Associated with Type 1 and 2 Diabetes: Productivity Loss and Medical Bills

US Antidiabetics Market Overview
7.1 Antidiabetic Injectable Market Trends in US
7.2 Antidiabetic Oral Drugs Market Trends in US
7.3 Commending Trends of Antidiabetics

US: Key Marketed Antidiabetic Drugs
8.1 Insulin Degludec (Tresiba)- Injection
8.2 Insulin Lispro - Injection
8.3 Insulin Inhalation(Afrezza) - Inhalation
8.4 Insulin Glargine (Toujeo) - Injection
8.5 Insulin Glulisine (Apidra) - Injection
8.6 Insulin Aspart (NovoLog) - Injection
8.7 Insulin Detemir (Levemir FlexTouch) - Injection
8.8 Insulin Glargine (Lantus) - Injection
8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection

US Biosimilar Insulin Market: Glargine Basaglar andndash; The First “Biosimilar” Insulin
9.1 First Insulin Biosimilar
9.2 Impact of Basaglar Launch

US Antidiabetics Drug Market Dynamics
10.1 Accelerative Parameters
10.2 Major Challenges

US Antidiabetics Drug Market Future Prospects

Competitive Landscape
12.1 AstraZeneca
12.2 Bayer
12.3 Boehringer Ingelheim
12.4 Eli-Lilly
12.5 Johnson and Johnson
12.6 Merck
12.7 Novartis
12.8 Novo Nordisk
12.9 Sanofi
12.10 Takeda

Figure 1-1: Illustration of the Categories of Diabetes Mellitus
Figure 1-2: Percentage of Different types of Antidiabetics Used
Figure 2-1: Historical Pathway of oral Diabetic Medication
Figure 3-1: Control of Glucose Uptake during Muscle Working
Figure 4-1: Categorization of Oral Antidiabetics Approved in US
Figure 4-2: Chemical Structure of Metformin, Phenformin and Buformin
Figure 4-3: Illustration of the Sub-Categories of Sulfonylureas
Figure 5-1: Mechanism of Insulin in Regulation of Blood Glucose Levels
Figure 5-2: Differences between Diabetes Mellitus 1 and 2 over Insulin
Figure 5-3: Structure of Differentiation of Peptidic Insulin Analogs
Figure 5-4: Demonstration of Action Profiles of Insulin Analogue
Figure 5-5: Activity Profiles of Different Types of Insulin
Figure 5-6: Difference between Lantus and Levemir
Figure 6-1: US: Number of Type 1 Diabetes Incidence (Million), 2016 and 2022
Figure 6-2: US: Number of Type 2 Diabetes Incidence (Million), 2014 - 2022
Figure 6-3: US: Type 1 Diabetes Prevalence Rate (%), 2016 and 2022
Figure 6-4: US: Type 2 Diabetes Prevalence Rate (%), 2014 - 2022
Figure 6-5: US: Diabetes Prevalence Rate among Adults Aged 18+ (%), 2010 - 2016
Figure 6-6: US: Obesity Rate Among Adults Aged 18+ (%), 2010 - 2016
Figure 6-7: US: Percentage of Adults with Obesity by State (%), 2015
Figure 6-8: Illustration of Total Cost of Diabetes Expenditure
Figure 6-9: Annual Average Cost Of Diabetes per Person in US
Figure 6-10: US: Productivity Loss Due To Type 1 Diabetes (US$ Billion), 2014 - 2022
Figure 6-11: US: Productivity Loss Due To Type 2 Diabetes (US$ Billion), 2014 - 2022
Figure 6-12: US: Medical Cost for Type 1 Diabetes (US$ Billion), 2014-2022
Figure 6-13: US: Medical Cost for Type 2 Diabetes (US$ Billion), 2014-2022
Figure 7-1: Overview of Diabetic Drug Market Segmentation
Figure 7-2: US: Antidiabetics Drug Market (US$ Billion), 2014 - 2022
Figure 7-3: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2016
Figure 7-4: US - Percentage of Most Common Class of Antidiabetics Drugs
Figure 7-5: US andndash; Percentage of Generally Prescribed Anti-Diabetic Drugs (%)
Figure 8-1: US - Insulin Degludec (Tresiba) Injection Sales (US$ Million), 2016-2022
Figure 8-2: US -Insulin Lispro Injection Sales (US$ Million), 2016-2022
Figure 8-3: US - Insulin Glargine (Toujeo) Injection Sales (US$ Million), 2016-2022
Figure 8-4: US - Insulin Glulisine (Apidra) Injection Sales (US$ Million), 2016-2022
Figure 8-5: US - Insulin Detemir (Levemir FlexTouch) Injection Sales (US$ Million), 2016-2022
Figure 9-1: Comparison of Price of Insulin Lantus and Basaglar
Figure 10-2: Estimated Insulin Basaglar Sales in Diabetes
Figure 10-1: Major Accelerative Parameters for Antidiabetic Market in US
Figure 10-2: Estimated Impact of Increasing Trend in Obesity by 2020
Figure 10-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050
Figure 10-4: Major challenges in Antidiabetics Market
Figure 10-5: Important Challenges with the Use of Insulin
Figure 11-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2022
Figure 11-2: Illustration of Antidiabetic Drugs Under Development

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Antidiabetics Drug Market Outlook 2022 Report here

News-ID: 1040634 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Figure

Floralite - Reduce Fat & Get Attractive Figure How To Buy!
Floralite Have you been working on your eating routine without seeing the results that you are anticipating? There is indeed thing called Floralite diet pills. Advantages of Floralite Floralite One of various things to esteem about this thing is that it's made expressly for the Floralite diet. That is an epic notwithstanding considering the way that when you use a thing that is custom fitted to work with the movements
THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER!
FOR IMMEDIATE RELEASE THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER! Contact: William Hirsch - Schlock Toys @ +1-949-677-9353 or DocSchlock@SchlockToys.com Featured on Tomi with Fox News host Tomi Lahren! SCHLOCK TOYS join forces with Kickstarter to Make Toys Great Again! The Kickstarter campaign page can be found HERE: https://www.kickstarter.com/projects/schlocktoys/collectors-edition-talking-trump-2020-man-of-action-figure/description “What a great message to be sent, and I think Trump himself would love this and that he’d be excited about it!” - Tomi Lahren, Fox News “You
Macarons Market Latest Sales Figure Signals More Opportunities Ahead
Global Macarons Sales Market(Sales,Revenue and competitors Analysis of Major Market)from 2014-2026 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Macarons Market. Some of the key players profiled in the study are La Dure,
Global Womens Figure Skates Market Growth 2019-2024
LP INFORMATION offers a latest published report on Womens Figure Skates Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Womens Figure Skates market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
Figure Skating Equipment Market Report 2018: Segmentation by Type (Figure Skate …
Global Figure Skating Equipment market research report provides company profile for SP-Teri, Graf Skate, Riedell Shoes, Roces, American Athletic, Rollerblade, Winnwell, Dongguan King Line, Jackson Ultima, HD Sports(MK Blades, John Wilson), Edea, Risport Skates, Paramount Skates and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY
Long-lasting Performance Improvement with Key Figure Analysis
Vienna/Reutlingen, October 17, 2012 – Manz, a leading high-tech mechanical engineering company, is optimizing its processes in strategic sourcing in order to recognize the risks and potential associated with each supplier early on so that the sourcing department can react to them in time. POOL4TOOL’s customized eSolutions localize and analyze key figures that are relevant to the decision making process, and displays these figures in a comprehensive and transparent way.